US 10370680
Method of treating factor IX deficiency using nuclease-mediated targeted integration
granted A61PA61P43/00A61P7/04
Quick answer
US patent 10370680 (Method of treating factor IX deficiency using nuclease-mediated targeted integration) held by Sangamo Therapeutics, Inc. expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Sangamo Therapeutics, Inc.
- Grant date
- Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 3
- CPC classes
- A61P, A61P43/00, A61P7/04